15 September 2022

COBALT completes patient recruitment

The COBALT study will provide evidence of the protective effect of coronavirus disease (COVID-19) vaccination in patients with chronic liver disease and help issue recommendations for future vaccination programs.

14 September 2022

A new EASL position paper reviews currently known liver-specific effects of COVID-19 and provides guidance on the care of adult liver patients

12 September 2022

Reframing our brand

It may be just a subtle change what you may have noticed, but for us at the European Foundation for the Study of Chronic Liver Failure represents a great improvement. Some fresh changes may be noticeable: the update of our logo which now displays new fonts and expansion of our color palette for a range of applications.

26 June 2022

New center in Europe elected member of the EASL-CLIF Consortium

The new member of the EASL-CLIF Consortium joins a network of more than 100 university hospitals and tertiary medical centers in Europe.

25 June 2022

The 2nd CHANCE Investigator Meeting brings together investigators around the globe to share their insights on project progress

The 2nd CHANCE Investigator Meeting took place on 24 June 2022 in London, UK.

24 June 2022

The EASL-CLIF Consortium Steering Committee meets to review and discuss progress of research activities in the previous year

The annual meeting of the EASL-CLIF Consortium Steering Committee took place on 23 June 2022 in London, UK.

23 June 2022

The General Assembly of the EASL-CLIF Consortium reunites its members in an extraordinary online meeting

The annual General Assembly of the EASL-CLIF Consortium took place in an online format on 21 June 2022 in London, UK.

01 June 2022

COVID-19 vaccination protects patients with liver disease or receiving liver transplant from infection

Collaborative research finds low risk of SARS-CoV-2 infection and mild symptoms in infected patients with cirrhosis, autoimmune liver disease or after liver transplantation following two doses of the COVID-19 vaccine.

16 May 2022

Liver transplantation for patients with ACLF: The knowns and unknowns

EF CLIF Scientific Director, Rajiv Jalan, presented progress of the CHANCE study at ILTS 2022.

16 May 2022

The 2nd A-TANGO General Assembly was held on 11–13 May 2022 in Castelldefels, Spain

More than one year after the kick-off meeting meeting of the EU-funded A-TANGO project, participants at partner institutions met for three days in Castelldefels, Spain, to discuss progress and the challenges of conducting a clinical trial to test the effectiveness and safety of a novel combinatorial therapy for the treatment of acute-on-chronic liver failure (ACLF).